Lv41
630 积分 2024-06-11 加入
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
1个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
1个月前
已关闭
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
1个月前
已完结
CD16A-Specific Tetravalent Bispecific Immune Cell Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) on Macrophages
1个月前
已关闭
Exploring the NK cell platform for cancer immunotherapy
1个月前
已完结
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
2个月前
已完结
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
3个月前
已完结
CAR T cell combination therapies to treat cancer
3个月前
已完结
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
4个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
4个月前
已完结
皖公网安备34019202002308
